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Hypertension or high blood pressure is a significant health problem worldwide. Bioactive peptides that inhibit angiotensin I converting
enzyme (ACE) in the cardiovascular system can contribute to the prevention and treatment of hypertension. These ACE inhibitory peptides
are derived from many food proteins, especially milk proteins. An ACE inhibitory activity in vitro does not always imply an antihyper-
tensive effect in vivo. Even if it does, it is very difficult to establish a direct relationship between in vitro and in vivo activity. This is
mainly due to the bioavailability of the ACE inhibitory peptides after oral administration and the fact that peptides may influence
blood pressure by mechanisms other than ACE inhibition. To exert an antihypertensive effect after oral ingestion, ACE inhibitory peptides
have to reach the cardiovascular system in an active form. Therefore, they need to remain active during digestion by human proteases and
be transported through the intestinal wall into the blood. The bioavailability of some ACE inhibitory peptides has been studied. It is also
known that (hydroxy)proline-containing peptides are generally resistant to degradation by digestive enzymes. Peptides can be absorbed
intact through the intestine by paracellular and transcellular routes, but the potency of the bioactivity after absorption is inversely corre-
lated to chain length. In addition, some strategies are proposed to increase the bioavailability of ACE inhibitory peptides. Further research
into the bioavailability of ACE inhibitory peptides will lead to the development of more effective ACE inhibitory peptides and foods.
Bioactive peptides: Hypertension: Gastrointestinal digestion: Intestinal transport
Nutrition science has evolved towards ‘nutrition for opti-
mal health’ in order to make a further contribution to dis-
ease prevention (Diplock et al. 1999). In this regard,
biologically active peptides have been characterised in a
number of natural and modified foods (Korhonen & Pih-
lanto, 2003). Angiotensin I converting enzyme (ACE)
inhibitory peptides are bioactive peptides with potential
antihypertensive properties in vivo. As hypertension is a
significant public health problem worldwide, these ACE
inhibitory peptides, as part of a food product or as nutra-
ceutical, may be of functional interest in maintaining a
healthy population.
Many studies have focused on the production and iso-
lation of ACE inhibitory peptides from different food pro-
teins (for reviews, see Yamamoto, 1997; FitzGerald &
Meisel, 2000; Pihlanto-Leppa¨la¨, 2001; Yamamoto et al.
2003). In order to reduce blood pressure after oral admin-
istration, ACE inhibitory peptides have to reach the blood-
stream in an active form. Hence, bioavailability of ACE
inhibitory peptides is needed to guarantee bioactivity.
This aspect has been considerably less investigated and is
discussed in the present review. After a general introduc-
tion to ACE inhibitory peptides and their use in the preven-
tion and treatment of hypertension, the disparity between in
vitro and in vivo activity is examined in the light of bio-
availability. An overview is given on the available litera-
ture on stability of bioactive peptides, particularly ACE
inhibitory peptides, against human proteases in the oral
delivery route and their intestinal transport. Finally, some
future perspectives are introduced, which may lead to
more effective ACE inhibitory peptides.
Angiotensin I converting enzyme inhibitory peptides
Biologically active peptides or functional peptides are food-
derived peptides that in addition to their nutritional value
exert a physiological effect in the body. These bioactive
peptides are inactive within the original protein but, once
released, function as regulatory compounds with hor-
mone-like activity that is based on the inherent amino
acid composition and sequence (Meisel, 1997b; Tome,
1998). In this regard, they may present active ingredients
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in functional foods and nutraceuticals (Meisel, 1997a; Clare
& Swaisgood, 2000). Numerous peptides exhibiting various
activities have been reported, including opiate, mineral
binding, immunomodulatory, ACE inhibitory, anti-throm-
botic and antimicrobial peptides (Meisel, 1998; Clare &
Swaisgood, 2000; Korhonen & Pihlanto, 2003). Bioactive
peptides usually contain two to twenty amino acid residues
per molecule. These peptides can be liberated from the
parent protein during gastrointestinal digestion in the
body or during food processing (Clare & Swaisgood,
2000). Although these exogenic peptides are less active
and less specific than their endogenic counterparts, they
can be effective after oral administration. They have partial
or total resistance to hydrolysis and may either enter peri-
pheral blood intact due to their low molecular size and
exert systemic effects, or produce local effects in the gastro-
intestinal tract (Yoshikawa et al. 2000).
Although other animal (as well as plant) proteins contain
potential bioactive sequences (Dziuba et al. 1999), milk
proteins are currently the main source of bioactive pep-
tides. Most major milk proteins have little or no bioactivity
in their native state. Proteolytic digestion of milk proteins,
however, releases and activates a plethora of bioactive pep-
tides. Some regions in the primary amino acid sequence of
milk proteins contain overlapping bioactive peptide
sequences, exerting different biological effects. These
regions in the multifunctional bioactive peptides are con-
sidered as ‘strategic zones’, which are partially protected
from proteolytic breakdown (Meisel & Bockelmann,
1999).
ACE plays an important role in the renin–angiotensin
system, which regulates arterial blood pressure as well as
salt and water balance. In the cardiovascular system,
ACE converts angiotensin I to angiotensin II, a potent
vasoconstrictor, and degrades bradykinin, a vasodilator
(Eriksson et al. 2002; Riordan, 2003). Therefore, inhibition
of ACE, by ACE inhibitory drugs like captopril and natural
ACE inhibitory peptides has been shown to result in an
antihypertensive effect in hypertensive human subjects
and animals (Takano, 1998; Cushman & Ondetti, 1999).
ACE inhibitory peptides derived from casein (casokinins)
and whey (lactokinins) have been isolated (FitzGerald &
Meisel, 2000; Pihlanto-Leppa¨la¨, 2001), in addition to
other vegetable and animal source proteins (Yamamoto,
1997; Yamamoto et al. 2003). It is only when these ACE
inhibitory peptides reach the cardiovascular system in an
active form that a blood-pressure-lowering effect is
induced.
As for the ACE inhibitory drugs, structure–activity
correlations between different peptide inhibitors of ACE
indicate that binding to ACE is strongly influenced by
the C-terminal tripeptide sequence of the substrate.
Although the precise substrate specificity is not fully
understood, ACE appears to prefer substrates or competi-
tive inhibitors containing hydrophobic (aromatic or
branched side-chains) amino acid residues at the three
C-terminal positions. However, a C-terminal lysine or argi-
nine, with a positive charge on the e-amino group, also
seems to contribute substantially to the inhibitory potency.
In this regard, it is postulated that the mechanism of ACE
inhibition involves inhibitor interaction with an anionic
binding site, which is distinct from the catalytic site. There-
fore, it is expected that peptide conformation, i.e. the struc-
ture adopted in a specific environment, should contribute to
ACE inhibitor potency. Due to substrate specificity differ-
ences between the two catalytic sites of ACE (Turner &
Hooper, 2002), ACE inhibitors may inhibit only one cata-
lytic site. Moskowitz (2003) proposes a model that
explains the clinical superiority of hydrophobic ACE
inhibitory drugs relative to hydrophilic ones. All ACE
inhibitors bind to the C-terminal catalytic site, but only
hydrophobic ones bind the occluded N-terminal catalytic
site and are therefore better at blocking angiotensin II pro-
duction. Moreover, this model can explain why hydro-
phobic ACE inhibitors have specific local benefits, e.g.
preventing organ damage, in addition to a reduction in
the systemic blood pressure (Moskowitz, 2003). A detailed
knowledge of ACE and the conformational behaviour of
ACE inhibitory peptides should lead to a better understand-
ing of the mechanism of action of natural ACE inhibitory
peptides (FitzGerald & Meisel, 2000).
Hypertension
Hypertension is a sustained increase in blood pressure and
is associated with greater risk for CVD. Hypertension is
one of the most common chronic medical conditions in
the developed world and is rapidly becoming a major prob-
lem in developing countries. It is estimated that about 20 %
of the world’s adult population suffers from hypertension.
The prevalence of high blood pressure increases with age,
affecting approximately 65 % of the population aged 65–
74 years in Western nations (Alper et al. 2001; Duprez
et al. 2002).
Lifestyle modifications and diet therapy are two of the
most important tools for effective lowering of blood
pressure (Hermansen, 2000). Moreover, even small
decreases in blood pressure result in significantly lower
risks for CVD (Van der Niepen, 2000). A higher dietary
protein intake seems to have favourable influences on the
blood pressure in hypertensive individuals (Stamler et al.
1996). In addition, the Dietary Approaches to Stop
Hypertension trial, a diet rich in fruits, vegetables and
low-fat dairy products, is associated with an effective
reduction in blood pressure (Harsha et al. 1999).
Although other mechanisms may play a role, ACE inhi-
bition by bioactive peptides released from food proteins
may have caused these antihypertensive effects. Indeed,
a number of research reports have demonstrated the
antihypertensive effect of ACE inhibitory peptides or
foods containing these bioactive compounds in hyperten-
sive patients, even when they received antihypertensive
medication (Hata et al. 1996; Itakura et al. 2001; Pins &
Keenan, 2002; Seppo et al. 2003). In addition, several
studies in spontaneously hypertensive rats (SHR) suggest
a significant suppression of the development of hyperten-
sion with a diet rich in ACE inhibitory peptides
(Yoshii et al. 2001; Sipola et al. 2002). Overall, this
points to the fact that ACE inhibitory peptides, as part
of a food product or as nutraceutical, may be of func-
tional interest in both the treatment and the prevention
of hypertension.
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Compared with ACE inhibitory drugs, food-derived pep-
tides have certain advantages. ACE inhibitory peptides
have lower ACE inhibitory activity in vitro than the ACE
inhibitory drugs, yet do not have the harmful side effects,
such as dry cough and angio-oedema, that are associated
with synthetically produced drugs (FitzGerald & Meisel,
2000; Riordan, 2003). They also represent a much lower
cost to health care. As part of the daily diet, they appear
more natural and safe to the consumer. Finally, food-
derived ACE inhibitory peptides fit well in the new nutri-
tion concept that emphasises the relationship between
nutrition and human health. However, ACE inhibitory
drugs have proven their usefulness. Therefore, it is not
the intention to completely replace them, but in a number
of cases, especially in the prevention of hypertension and
as initial treatment in mildly hypertensive individuals,
food-derived ACE inhibitory peptides could be applied,
while in others they could function as an additional
treatment.
Angiotensin I converting enzyme inhibitory activity v.
antihypertensive effect
ACE inhibitory activity is usually analysed in vitro
and implies the determination of the ACE activity by
means of synthetic substrates with amino-substituted tri-
and dipeptides, such as hippuryl-L-histidyl-L-leucine
(Cushman & Cheung, 1971; Nakamura et al. 1995), 2-fur-
anacryloyl-L-phenylalanyl-L-glycyl-L-glycine (Holmquist
et al. 1979; Vermeirssen et al. 2002b) and dansyltriglycine
(Elbl & Wagner, 1991), via radioisotopic, spectrophoto-
metric, fluorometric and chromatographic methods. While
ACE inhibitory activity is a marker for a biological
response, the demonstration of an antihypertensive effect
represents an intermediate endpoint marker for CVD
(Diplock et al. 1999). Antihypertensive effects can be
measured in SHR, which are genetically predisposed to
have a high blood pressure (Yigal et al. 1998), and in clini-
cal trials with hypertensive patients. As an example of the
structure–activity relationship, the ACE inhibitory activity
of dipeptides with tyrosine is higher than those with
phenylalanine, but less than dipeptides with proline at the
C-terminal (Cheung et al. 1980). After oral administration
in SHR, dipeptides with tyrosine at the C-terminal caused
slow but prolonged reduction of the systolic blood pressure
compared with dipeptides with phenylalanine at the car-
boxy-terminus, which produced a more rapid decrease
and a shorter duration of action (Suetsuna, 1998).
However, it is difficult to establish a direct relationship
between ACE inhibitory activity in vitro and antihyperten-
sive activity in vivo. First, the bioavailability after oral
administration plays a major role. To exert physiological
effects in vivo after oral ingestion, it is of crucial import-
ance that ACE inhibitory peptides remain active during
gastrointestinal digestion and absorption and reach the car-
diovascular system. ACE inhibitory peptides may be
released and degraded in the human body. Fig. 1 shows
the potential barriers in the human body where bioactive
peptides can be (in)activated. This will be further discussed
later for bioactive peptides. Second, antihypertensive
mechanisms other than ACE inhibition may be of interest.
In the case of the opiate and ACE inhibitory peptide
a-lactorphin, originally derived from bovine a-lactalbu-
min, the opiate activity causes the dose–dependent
reduction in the blood pressure of SHR and normotensive
Wistar–Kyoto rats upon subcutaneous administration, as
the effect can be reversed by nalaxone, a specific opiate
receptor antagonist (Nurminen et al. 2000). Single oral
administration of an extract from autologous lysate of
Lactobacillus casei significantly lowers the blood pressure
in SHR and long-term oral administration even suppresses
the development of hypertension in these animals
(Furushiro et al. 1990). The active substance in this extract,
a polysaccharide–glycopeptide complex, enhances prosta-
glandin synthesis only after oral intake; this results in a
decrease of peripheral vascular resistance and hence an
antihypertensive effect (Furushiro et al. 1993). Further-
more, oral administration of the Lactobacillus casei cell
lysate extract to hypertensive patients reduces both the
systolic and diastolic blood pressure, in addition to the
total cholesterol and fasting plasma glucose level
(Nakajima et al. 1995). In SHR, two peptides, the ovokinin
phenylalanine-arginine-alanine-aspartate-histidine-proline-
phenylalanine-leucine and arginine-alanine-aspartate-histi-
dine-proline-phenylalanine (isolated from a pepsin and
a-chymotrypsin digest of ovalbumin respectively), exert
a dose-dependent vasodilatation in an isolated mesenteric
artery that is preconstricted by phenylephrine. The vasore-
laxing activity is attributable to the binding to B1 receptors
and the subsequent release of prostaglandin and NO.
Following oral administration, arginine-alanine-aspartate-
histidine-proline-phenylalanine lowers the blood pressure
in SHR (Fujita et al. 1995; Matoba et al. 1999).
An even more potent and long-lasting hypotensive activity
is obtained by oral administration of the synthetic
analogue arginine-proline-phenylalanine-histidine-proline-
phenylalanine (Matoba et al. 2001). Pepsin digests of
bonito and beef inhibit the endothelin converting enzyme,
which produces the potent vasoconstrictor endothelin
(Okitsu et al. 1995; Maes et al. 2004). Furthermore, it
has also been suggested that ACE inhibitory peptides
may exert an additional antihypertensive effect by inhi-
bition of chymase (Yamamoto et al. 1999).
In addition, different ACE inhibition assays, where other
substrates and calculations for the median inhibitory con-
centration (IC50) are used, hamper the comparison of
ACE inhibitory activities. In addition, in in vivo experi-
ments and clinical trials, different experimental designs
(measurement of the mean arterial or systolic and/or dia-
stolic blood pressure; intravenous, subcutaneous or oral
administration; other doses) and the use of the SHR
model v. the hypertensive patient hinder stating an unequi-
vocal effect. Although the IC50 of captopril is about
1000-fold lower than that of food-derived ACE inhibitory
peptides, there is no discrepancy observed in the antihyper-
tensive effect. Indeed, oral administration of 200 mg/kg
body weight dipeptide isolated from garlic results in a
reduction of blood pressure in SHR of about 30 mmHg,
while captopril at a dose of 10 mg/kg body weight
exerts an antihypertensive effect of about 50 mmHg
(Suetsuna, 1998). There are no substantial differences in
duration of the effect. When compared on molar basis,
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the antihypertensive activity of leucine-lysine-proline after
oral and intravenous administration in SHR amounted to 91
and 20 % of that of captopril respectively, whereas the in
vitro ACE inhibitory activity was 7·73 % compared with
captopril (Fujita & Yoshikawa, 1999). Hence, these find-
ings indicate that compared with antihypertensive drugs,
food-derived ACE inhibitory peptides with antihyperten-
sive activity possess higher in vivo activity than would be
expected from their in vitro activity. A sound explanation
for this observation cannot be proposed yet, but in addition
to the reasons mentioned earlier, it has been suggested that
food-derived peptides have higher affinities for tissues and
are more slowly eliminated than the synthetic captopril
(Fujita & Yoshikawa, 1999). Moreover, it is plausible
that the access to the ACE enzyme in vivo is limited, so
that above a certain affinity substances inhibit ACE in
vivo to a similar extent. After feeding 100 mg soy-protein
hydrolysate/kg body weight to SHR for 1 month, blood
pressure decreased by 38 mmHg, compared with
46 mmHg on providing 50 mg captopril/kg body weight
(Wu & Ding, 2001). When assessing the ACE activity in
serum, aorta and lung of these rats, the soy-protein ACE
inhibitory peptides did not show any significant effect com-
pared with the control, whereas captopril greatly enhanced
the ACE activity in serum and reduced the ACE activity in
the aorta. Although the real causes of these observations
remain unknown, these different responses might indicate
that food-derived ACE inhibitory peptides and captopril
act via different antihypertensive mechanisms.
Hence, further investigation into the antihypertensive
effect of food-derived ACE inhibitory peptides is necess-
ary. In vivo experiments and clinical trials are necessary
to demonstrate their physiological effects. However, evi-
dence of in vitro ACE inhibitory activity is a good starting
point, because it is based on a biological mechanism.
As ACE exhibits several functions in the human body,
ACE inhibition may have additional or other implications
than antihypertensive effects (Moskowitz, 2002).
Gastrointestinal digestion
Digestion of proteins starts in the stomach by the action
of pepsin at acidic pH. In the luminal phase of the small
Fig. 1. The potential activation and inactivation of angiotensin I converting enzyme (ACE) inhibitory peptides in the human body during gastro-
intestinal digestion and absorption, and in the blood.
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intestine, the polypeptides are further cleaved by the
pancreatic proteases trypsin, a-chymotrypsin, elastase and
carboxypeptidase A and B at more alkaline pH. This results
in a mixture of oligopeptides and free amino acids, of
which oligopeptides constitute a major portion. The free
amino acids are absorbed as such into the enterocytes
across the brush border membrane via distinct amino
acid transport systems. The oligopeptides undergo further
hydrolysis by the action of a battery of brush border pepti-
dases, resulting in a mixture largely consisting of free
amino acids and di- and tripeptides. The intestinal brush
border membrane is particularly rich in aminopeptidase
activity, which provides functional complementation to
the carboxypeptidases present in the pancreatic juice.
Aminopeptidase N and A are the major representatives
and cleave N-terminal neutral and anionic amino acids
respectively. In addition to these enzymes, the intestinal
brush border contains endopeptidase and dipeptidase
activity. ACE or dipeptidyl carboxypeptidase cleaves
dipeptides from the C-terminus of oligopeptides with
proline, phenylalanine or leucine in the ultimate position.
Dipeptidyl aminopeptidase IV releases dipeptides from
the N-terminus of oligopeptides with proline or alanine
in the penultimate position. Hence, the dipeptides released
by these enzymes are generally of the X-proline type
(Ganong, 1997; Ganapathy & Leibach, 1999).
Proline- and hydroxyproline-containing peptides are
generally resistant to degradation by digestive enzymes.
Furthermore, tripeptides containing the C-terminal proline-
proline are reported to be resistant to proline-specific pep-
tidases (Vanhoof et al. 1995; FitzGerald & Meisel, 2000).
This stresses the fact that several bioactive peptides that
have been shown to exert an in vivo effect are isolated
from casein and gelatine, as these proteins have a high
proline content.
Bioactive peptides have already been characterised from
in vivo digests. When diets containing bovine casein are
given to minipigs, the opiate peptide b-casomorphin-11
and the mineral binding casein phosphopeptide as1-casein
f(66-74) are isolated from small intestinal contents
(Meisel & Frister, 1989). In another study, b-casomor-
phin-7 immunoreactive material was detected in small
intestinal contents of adult human subjects after bovine
milk ingestion (Svedberg et al. 1985). In adult human sub-
jects after milk or yoghurt ingestion, the appearance of bio-
active peptides in the stomach, small intestine and blood
has been investigated. Many peptides derived from as1-,
b- or k-caseins have been detected in the stomach, smaller
peptides derived from casein and lactoferrin have been
recovered from the small intestine. Two long peptides,
casein glycomacropeptide, k-casein f(106-117) and the
N-terminal peptide f(1-23) of as1-casein, are absorbed
and detected in plasma (Chabance et al. 1998). Hence,
casoplatelines (casein glycomacropeptide fragments) are
released during gastrointestinal digestion and absorbed
intact into the blood, which supports the concept that they
exert an anti-thrombotic effect in vivo. The peptide phenyl-
alanine-valine-alanine-proline-phenylalanine-proline-gluta-
mate-valine-phenylalanine-glycine-lysine-glutamate, and
as1-casein f(24-35) and f(25-32), are released in the
human stomach. The fragments f(25-32) and f(28-35) are
also detected in the duodenum. As these contain sequences
of ACE inhibitory peptides (Maruyama et al. 1987; Karaki
et al. 1990), they might exert a physiological effect after
absorption in the blood. The peptide as1-casein f(1-23) is
the antibacterial peptide isradicin with immunomodulatory
capacities. This includes the fragment as1-casein f(1-9),
arginine-proline-lysine-histidine-proline-isoleucine-lysine-
histidine-glutamine, which has been shown to have a small
antihypertensive effect in SHR (Saito et al. 2000).
To investigate whether ACE inhibitory peptides resist
gastrointestinal digestion, they are usually subjected in
vitro to hydrolysis by pepsin, trypsin, a-chymotrypsin or
pancreatin. For example, ACE inhibitory wheatgerm
hydrolysate and the peptide isoleucine-valine-tyrosine iso-
lated from it are hydrolysed by pepsin, trypsin and a-chy-
motrypsin alone and in combination. The ACE inhibitory
activity of the wheatgerm hydrolysate increases by 27 %
after a combined digestion, indicating that any active pep-
tides must be newly produced by action of these proteases,
in particular trypsin. The IC50 value of isoleucine-valine-
tyrosine does not change during digestion, signifying that
this peptide would resist in vivo gastrointestinal digestion
(Matsui et al. 1999). We also observed that high ACE
inhibitory activity was produced upon in vitro gastrointes-
tinal digestion of pea and whey protein (Vermeirssen et al.
2003a,b). Another example of activation of ACE inhibitory
peptides during gastrointestinal digestion is as follows.
The antihypertensive peptide lysine-valine-leucine-pro-
line-valine-proline-glutamine showed only low ACE
inhibitory activity in vitro. However, the potent ACE
inhibitor lysine-valine-leucine-proline-valine-proline was
formed after pancreatic digestion due to the action of car-
boxypeptidase A. In the same study, an as1-casein-derived
peptide, tyrosine-lysine-valine-proline-glutamine-leucine,
with strong ACE inhibitory activity, failed to exert an anti-
hypertensive effect due to pancreatin degradation (Maeno
et al. 1996).
After the small intestine, the non-digested and/or non-
absorbed food peptides enter the large intestine or colon,
where they can be metabolised by the intestinal microbiota.
Whether ACE inhibitory peptides can still exert an antihy-
pertensive effect after they enter this compartment needs to
be investigated.
Intestinal absorption
Peptides consisting of two or three amino acids are
absorbed intact across the brush border membrane by a
specific peptide transport system. The peptide transporter
PepT1 uses a transmembrane electrochemical proton gradi-
ent as the driving force and has broad substrate specificity
(Yang et al. 1999). Small peptides are absorbed more
rapidly than free amino acids and their transport is favoured
(Webb, 1990). Once inside the enterocyte, these peptides
are usually hydrolysed to free amino acids in the cytoplasm
by various intracellular peptidases. Among these, aminotri-
peptidase, which releases the amino acid from the N-termi-
nus of tripeptides, and several dipeptidases with different
substrate specificity towards specific amino acids, are pre-
sent. Here, iminodipeptidase or prolidase is of special inter-
est because of its restricted specificity toward dipeptides of
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the X-proline or X-hydroxyproline type. Via specific amino
acid transport systems, the amino acids cross the basolat-
eral membrane and enter the portal circulation (Ganapathy
& Leibach, 1999).
Transport of intact peptides and proteins from the intes-
tinal lumen into the blood circulation is a unique phenom-
enon, which differs from the regular process of food
digestion and absorption. The concept that significant
amounts of small peptides can escape total digestion to
amino acids and enter the circulation in intact form is
rather new, but is gaining acceptance (Gardner, 1988;
Grimble, 2000). Apart from the peptide transporter route,
peptides can be absorbed intact across the intestinal
mucosa via other mechanisms (Fig. 2) (Gardner, 1998).
There is evidence in support of both paracellular and trans-
cellular routes for passage of intact peptides, but there is
still debate as to the relative importance of these. Paracel-
lularly, large water-soluble peptides pass via the tight junc-
tions between cells. Highly lipid-soluble peptides appear to
be able to diffuse via the transcellular route. Peptides may
also enter the enterocytes via endocytosis, which entails
membrane binding and vesiculisation of the material (Ziv
& Bendayan, 2000). The intestinal basolateral membrane
also possesses a peptide transporter, which facilitates the
exit of hydrolysis-resistant small peptides from the entero-
cyte into the portal circulation (Gardner, 1984).
Biologically active peptides generated in the diet can be
absorbed intact through the intestine and produce biologi-
cal effects at the tissue level. However, the potency of
the administered peptides decreases as the chain-length
increases (Roberts et al. 1999). As in infants, the gastroin-
testinal barrier is not yet completely mature, intact peptides
and proteins are much better absorbed in infants than in
adults (Walker, 1985). Together with the limited gastroin-
testinal proteolysis in infants, this explains why milk con-
tains several bioactive proteins and peptides that are
thought to have a physiological role in the young.
In this regard, b-casomorphin-immunoreactive material
is detected in the plasma of newborn calves after milk
intake (Umbach et al. 1985). Higher plasma levels of
casein glycomacropeptide are found in 5-d-old infants com-
pared with human adults after ingestion of milk (Chabance
et al. 1995, 1998). In the latter study, it was demonstrated
that a peptide containing twenty-four amino acids is
absorbed intact into the bloodstream of human adults after
milk ingestion (see earlier; Chabance et al. 1998). Intestinal
transport of b-casomorphins and synthetic analogues is
investigated in isolated rabbit ileum mounted in Ussing
chambers. While natural b-casomorphins are degraded by
the intestinal mucosa and no intact transepithelial passage
is detected for these peptides, the synthetic analogue
tyrosine-D-alanine-phenyalanine-D-alanine-tyrosine crosses
the epithelium intact (Tome et al. 1987).
When the intestinal transport mechanism of the antihy-
pertensive peptide valine-proline-proline is studied in a
Caco-2 cell monolayer, a small but significant amount of
intact valine-proline-proline is transported through the
cell monolayer. Despite a flux of ,2 % per h in the
Caco-2 cell monolayer, the tripeptide has been shown to
be present in the abdominal aorta and exerts an antihyper-
tensive effect after oral intake in SHR (Masuda et al.
1996). The transport of valine-proline-proline is not
mediated by the peptide transporter PepT1 and it has
been suggested that paracellular transport is the main
mechanism of absorption (Satake et al. 2002). In another





tyrosine-arginine was investigated in the Caco-2 model.
The susceptibility to the brush border peptidases was
one of the factors that decided the transport rate. Bradyki-
nin and glycine-glycine-tyrosine-arginine were hardly
degraded, while b-casomorphin and ovokinin were sub-
stantially hydrolysed. The transport rate was greatest for
glycine-glycine-tyrosine-arginine and smallest for b-caso-
morphin. Furthermore, the transport mechanism was stu-
died for bradykinin and glycine-glycine-tyrosine-arginine.
While adsorptive transcytosis through hydrophobic inter-
action with the cell membrane was suggested to be
involved in the transport of bradykinin, glycine-glycine-
tyrosine-arginine was believed to be transported mainly
via the paracellular pathway. It seems that molecular size
and other structural properties, such as hydrophobicity,
determine the major transport route for peptides (Shimizu
et al. 1997).
The antihypertensive peptide valine-tyrosine, derived
originally from sardine muscle, is detected dose-dependently
in human plasma and reaches a maximum 2 h after a single
oral administration in normotensive human subjects. At the
highest dose, more than a 10-fold greater increment in
valine-tyrosine plasma concentration is measured compared
with the baseline concentration. The low absorption ratios
are explained by the fact that most of the administered dipep-
tide is hydrolysed by membrane-bound peptidases. There-
fore, it is suggested that saturation of the peptide
transporter enables the entry of excess valine-tyrosine into
peripheral blood (Matsui et al. 2002b).
When the transport of the lactokinin alanine-leucine-pro-
line-methionine-histidine-isoleucine-arginine was studied
in a Caco-2 Bbe cell monolayer, this peptide was found to
be absorbed at low concentrations (Vermeirssen et al.
2002a).
Few studies on the transport of ACE inhibitory peptides
have been undertaken, although it is important for the bio-
availability of these peptides to investigate whether they
are transported and what the transport mechanism is. Gen-
erally, the Caco-2 cell monolayer is used to investigate
intestinal transport. This confluent cell monolayer displays
Fig. 2. Mechanisms for intestinal transport of peptides: (1),
paracellular; (2), passive diffusion; (3) endocytosis; (4) carrier-
mediated transport.
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several properties typical of differentiated intestinal epi-
thelial cells (Wilson et al. 1990) and is widely used as a
model in transport studies of drugs (Augustijns et al.
1998; Boisset et al. 2000) and food compounds (Rubio &
Seiquer, 2002). Caco-2 cell monolayers are known to be
tighter than mammalian intestinal tissues (Boisset et al.
2000), while brush border membrane-associated enzyme
activities are generally lower (Bolte et al. 1998). Species-
specific differences in intestinal brush border enzyme
activity have been observed (Drucker et al. 1997). For
example, esterase activities in homogenates prepared
from freshly scraped intestinal rat mucosa is up to six
times greater than that of pig, the latter being considered
more representative for the human small intestine
(Augustijns et al. 1998). In order to get an overview of
the transport possibilities and limitations of a certain com-
pound, it is advisable to apply different absorption models.
Therefore, intestinal transport in vivo might be more pro-
nounced than observed in the Caco-2 cell monolayer. In
addition, during oral consumption of ACE inhibitory pep-
tides, the presence of other food compounds may have
important consequences on the susceptibility to peptidase
degradation and intestinal transport (Charman et al.
1997). While some specific food compounds have been
observed to decrease the transepithelial electrical resistance
in the Caco-2 cell monolayer (Shimizu, 1999), active trans-
port of sugars and amino acids initiates a solvent drag
through the tight junctions in rat intestine, by which oligo-
peptides may be absorbed (Pappenheimer & Volpp, 1992).
This could be an additional advantage of protein hydroly-
sates containing amino acids compared with pure peptides.
Stability in the blood
Blood contains substantial activities of peptidase enzymes.
The half-life of certain peptides in plasma is very short,
with an order of magnitude of 1 min (Gardner, 1998).
Angiotensin II degradation occurs even within seconds
(Moskowitz, 2003).
First, oligopeptides with an ACE inhibitory activity in
vitro need to resist ACE to exert an antihypertensive
effect in vivo. In this regard, the ACE inhibitory peptides
can be classified into three groups: the inhibitor type, of
which the IC50 values are not affected by preincubation
with ACE; the substrate type, peptides that are hydrolysed
by ACE to give peptides with a weaker activity; the pro-
drug-type inhibitor, peptides that are converted to true
inhibitors by ACE or other gastrointestinal proteases.
Only peptides belonging to the inhibitor or pro-drug type
exert antihypertensive activities after oral administration
in SHR (Fujita et al. 2000).
After intravenous administration to SHR of the ACE
inhibitory peptide isoleucine-valine-tyrosine, isolated
from wheatgerm hydrolysate, the tripeptide is metabolised
by the action of aminopeptidase in plasma to form a
subsequent ACE inhibitor, valine-tyrosine. Valine-tyrosine
exerts an acute depressor effect in SHR and the blood
pressure returns to the normal state about 5 min after injec-
tion. On the other hand, after injection of isoleucine-valine-
tyrosine, the reduction in blood pressure is much stronger
and is held for 15 min. Therefore, it is suggested that the
intake of isoleucine-valine-tyrosine as a physiologically
functional food would serve in lowering blood pressure
by the combined action of itself and its metabolite after
absorption (Matsui et al. 2000). Valine-tyrosine has been
administered orally to mild hypertensive subjects.
Although the peptide is present in plasma and the absorp-
tion is comparable with that observed in normotensive sub-
jects (see earlier), no marked decrease in blood pressure
was seen, suggesting that the peptide exerts no acute hypo-
tensive effect (Matsui et al. 2002a).
Future perspectives
Several food products contain ACE inhibitory peptides that
are known to reach the cardiovascular system and exert an
antihypertensive effect. Further research into the bioavail-
ability and the structure–activity can improve the isolation
and production of effective ACE inhibitory peptides.
Despite their susceptibility to metabolism and some-
times low membrane permeability, peptides have been
recognised as important therapeutic compounds and there-
fore several approaches have been designed to increase the
oral delivery of peptides. First, peptides can be chemically
modified to increase their oral delivery (Brayden &
O’Mahony, 1998; Dooley & Houghten, 1999; Mayo,
2000). Second, ACE inhibitory peptides can be produced
by genetic engineering in a micro-organism and sub-
sequently delivered in situ. For example, oligonucleotides
encoding the ACE inhibitory peptides isoleucine-tyrosine
and valine-lysine-tyrosine are chemically synthesised and
designed to be multimerised due to isoschizomer sites.
The cloned gene, named ap3, is multimerised up to six
times in a plasmid and expressed as a fusion protein in
Escherichia coli, which is easily purified. The digest of
AP3 by chymotrypsin has an IC50 value of 18·53mM.
Therefore, potent ACE inhibitory peptides may be released
upon oral ingestion of AP3 (Oh et al. 2002). Several
expression vector systems are commercially available to
yield substantial amounts of designed proteins. Most of
them, however, make the subsequent purification of the
artificial protein necessary because the expressed protein
resides in the host cell, as described by Oh et al. (2002).
In the same way as therapeutic compounds are delivered
in situ by genetically engineered micro-organisms
(Kru¨ger et al. 2002; Steidler, 2002), ACE inhibitory pro-
peptides could be delivered to the small intestine, where
they could be expressed and exported outside the cell,
cleaved into active peptides by the action of proteases
and/or peptidases and finally transported into the blood
stream. A generally recognised as safe (GRAS) micro-
organism that is able to survive the gastrointestinal transit
and has additional probiotic properties could be selected.
This bacterium should be genetically engineered to express
upon induction the ACE inhibitory propeptide, coupled to a
signal peptide to direct the translocation of the protein
through the cell membrane. An inducible promoter
should increase ACE inhibitory peptide release in the
small intestine and prevent the expression of the polypep-
tide in the large intestine, where it is of no use and could
eventually lead to the formation of harmful N-compounds.
When further research has guaranteed the safety of GM
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organisms, a functional food based on this concept might
have great value, because it not only would enhance the
oral delivery of ACE inhibitory peptides, but it would
also enable the combination of different functional effects
in one food. In addition to micro-organisms, genetic engin-
eering may also be applied to plants and animals, where
modified proteins, rich in ACE inhibitory peptide
sequences, could be obtained.
The bioavailability of ACE inhibitory peptides may also
be increased by cross-linking the target peptide to protein
transduction domains or by means of specific peptide car-
riers like Pep-1 that are able to deliver biologically active
proteins and peptides into mammalian cells (Morris et al.
2001). Peptide permeation may also be achieved by chemi-
cal enhancers and surfactant-like agents, provided the
tissue recovers in vivo after temporary exposure. Receptor
targeting and mucoadhesion represent some other strate-
gies that may increase the delivery of peptides (Brayden
& O’Mahony, 1998).
Conclusion
The antihypertensive effect of ACE inhibitory peptides is
strongly influenced by their bioavailability, which is predo-
minantly determined by the resistance to peptidase degra-
dation and intestinal absorption. This should be taken
into account when developing food products containing
ACE inhibitory peptides.
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